BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 7734612)

  • 1. [Modern representations of multiple forms of cyclic nucleotide phosphodiesterases in mammalian tissues].
    Medvedeva MV
    Biokhimiia; 1995 Mar; 60(3):364-86. PubMed ID: 7734612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Kinetic properties and regulation of cyclic nucleotide phosphodiesterases in lymphoid cells].
    Azhaeva EV; Severin ES
    Bioorg Khim; 1987 Sep; 13(9):1157-63. PubMed ID: 2827690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypertrophied right hearts get two for the price of one: can inhibiting phosphodiesterase type 5 also inhibit phosphodiesterase type 3?
    Kass DA
    Circulation; 2007 Jul; 116(3):233-5. PubMed ID: 17638937
    [No Abstract]   [Full Text] [Related]  

  • 4. Modulation of rat thymocyte proliferative response through the inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents.
    Marcoz P; Prigent AF; Lagarde M; Nemoz G
    Mol Pharmacol; 1993 Nov; 44(5):1027-35. PubMed ID: 8246905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Properties of cyclic nucleotide phosphodiesterase from lingual taste papillae].
    Ostretsova IB
    Biokhimiia; 1978 Jun; 43(6):1037-44. PubMed ID: 27246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Phosphodiesterases of cyclic GMP].
    Wróblewska H; Gorczyca WA
    Postepy Hig Med Dosw; 2001; 55(5):611-27. PubMed ID: 11795198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Membraneous and cytosolic cyclic-nucleotide phosphodiesterases in beef aorta: substrate specificity, endogenous inhibition and activation [proceedings].
    Ilien B; Morel A; Stierle A; Landry Y
    Arch Int Physiol Biochim; 1978 Oct; 86(4):865-7. PubMed ID: 84582
    [No Abstract]   [Full Text] [Related]  

  • 8. General properties of multiple molecular forms of cyclic nucleotide phosphodiesterase in the nervous system.
    Strada SJ; Martin MW; Thompson WJ
    Adv Cyclic Nucleotide Protein Phosphorylation Res; 1984; 16():13-29. PubMed ID: 6326518
    [No Abstract]   [Full Text] [Related]  

  • 9. Cyclic nucleotides and cyclic nucleotide phosphodiesterases in kidneys from rats with experimental diabetes.
    Hoskins B; Luong HB
    Res Commun Chem Pathol Pharmacol; 1981 Aug; 33(2):381-4. PubMed ID: 6272381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of cyclic nucleotide phosphodiesterase activity.
    Vaughan M; Danello MA; Manganiello VC; Strewler GJ
    Adv Cyclic Nucleotide Res; 1981; 14():263-71. PubMed ID: 6169258
    [No Abstract]   [Full Text] [Related]  

  • 11. Pig aortic endothelial-cell cyclic nucleotide phosphodiesterases. Use of phosphodiesterase inhibitors to evaluate their roles in regulating cyclic nucleotide levels in intact cells.
    Souness JE; Diocee BK; Martin W; Moodie SA
    Biochem J; 1990 Feb; 266(1):127-32. PubMed ID: 2155604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclic nucleotide phosphodiesterase of normal and leukemic lymphocytes. Kinetic properties and selective alteration of the activity of the multiple molecular forms.
    Hait WN; Weiss B
    Mol Pharmacol; 1979 Nov; 16(3):851-64. PubMed ID: 231197
    [No Abstract]   [Full Text] [Related]  

  • 13. Cyclic-GMP-regulated enzymes and their possible physiological functions.
    Walter U
    Adv Cyclic Nucleotide Protein Phosphorylation Res; 1984; 17():249-58. PubMed ID: 6145321
    [No Abstract]   [Full Text] [Related]  

  • 14. [Separation and investigation of the regulatory properties of two forms of cyclic nucleotide phosphodiesterase from rabbit heart--sensitive and insensitive to Ca-dependent regulator protein].
    Tkachuk VA; Lazarevich VG; Men'shikov MIu; Severin SE
    Biokhimiia; 1978 Sep; 43(9):1622-30. PubMed ID: 214170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between inhibition of cardiac muscle phosphodiesterases, changes in cyclic nucleotide levels, and contractile response for CI-914 and other novel cardiotonics.
    Weishaar RE; Quade MM; Schenden JA; Evans DB
    J Cyclic Nucleotide Protein Phosphor Res; 1985; 10(6):551-64. PubMed ID: 3003170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclic nucleotide phosphodiesterase activity in patients with obstructive airways disease.
    Polson JB; Krzanowski JJ; Goldman AL; Szentivanyi A
    Allergol Immunopathol (Madr); 1982; 10(2):101-4. PubMed ID: 6125092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships.
    Ko WC; Shih CM; Lai YH; Chen JH; Huang HL
    Biochem Pharmacol; 2004 Nov; 68(10):2087-94. PubMed ID: 15476679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implications of PDE4 structure on inhibitor selectivity across PDE families.
    Ke H
    Int J Impot Res; 2004 Jun; 16 Suppl 1():S24-7. PubMed ID: 15224132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stimulation of hamster adipocyte cyclic 3':5'-nucleotide phosphodiesterase activity by ionophore A23187 and calcium.
    Nemecek GM
    J Cyclic Nucleotide Res; 1978 Aug; 4(4):299-309. PubMed ID: 214467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis.
    Piazza GA; Thompson WJ; Pamukcu R; Alila HW; Whitehead CM; Liu L; Fetter JR; Gresh WE; Klein-Szanto AJ; Farnell DR; Eto I; Grubbs CJ
    Cancer Res; 2001 May; 61(10):3961-8. PubMed ID: 11358813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.